BACKGROUND: Colorectal cancer is a highly prevalent and deadly. The most common metastatic site is the liver. We performed a whole exome sequencing analysis of a series of metachronous colorectal cancer liver metastases (mCLM) and matched non-malignant liver tissues to investigate the genomic profile of mCLM and explore associations with the patients' prognosis and therapeutic modalities. METHODS: DNA samples from mCLM and non-malignant liver tissue pairs (n = 41) were sequenced using whole exome target enrichment and their germline and somatic genetic variability, copy number variations, and mutational signatures were assessed for associations with relapse-free (RFS) and overall survival (OS). RESULTS: Our genetic analysis could stratify all patients into existing targeted therapeutic regimens. The most commonly mutated genes in mCLM were TP53, APC, and KRAS together with PIK3CA and several passenger genes like ABCA13, FAT4, PCLO, and UNC80. Patients with somatic alterations in genes from homologous recombination repair, Notch, and Hedgehog pathways had significantly prolonged RFS, while those with altered MYC pathway genes had poor RFS. Additionally, alterations in the JAK-STAT pathway were prognostic of longer OS. Patients bearing somatic variants in VIPR2 had significantly shorter OS and those with alterations in MUC16 prolonged OS. Carriage of the KRAS-12D variant was associated with shortened survival in our and external datasets. On the other hand, tumor mutation burden, mismatch repair deficiency, microsatellite instability, mutational signatures, or copy number variation in mCLM had no prognostic value. CONCLUSIONS: The results encourage further molecular profiling for personalized treatment of colorectal cancer liver metastases discerning metachronous from synchronous scenarios.

Department of Biology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Surgery Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Laboratory of Pharmacogenomics Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen 306 05 Czech Republic

Toxicogenomics Unit National Institute of Public Health Prague Czech Republic

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660. PubMed DOI

Rawla P, Sunkara T, Barsouk A. Epidemiology of Colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad Gastroenterologiczny. 2019;14(2):89–103. PubMed PMC

Biller LH, Schrag D. Diagnosis and treatment of metastatic Colorectal Cancer: a review. JAMA. 2021;325(7):669–85. doi: 10.1001/jama.2021.0106. PubMed DOI

Colloca GA, Venturino A, Guarneri D. Different variables predict the outcome of patients with synchronous versus metachronous metastases of Colorectal cancer. Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2020;22(8):1399–406. doi: 10.1007/s12094-019-02277-7. PubMed DOI

Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P. The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis. 2013;30(4):457–70. doi: 10.1007/s10585-012-9551-8. PubMed DOI

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, et al. NCCN guidelines insights: Colon Cancer, Version 2.2018. J Natl Compr Cancer Network: JNCCN. 2018;16(4):359–69. doi: 10.6004/jnccn.2018.0021. PubMed DOI PMC

Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. doi: 10.1038/nature11252. PubMed DOI PMC

Tang J, Tu K, Lu K, Zhang J, Luo K, Jin H, Wang L, Yang L, Xiao W, Zhang Q, et al. Single-cell exome sequencing reveals multiple subclones in metastatic colorectal carcinoma. Genome Med. 2021;13(1):148. doi: 10.1186/s13073-021-00962-3. PubMed DOI PMC

Yi H, Liao ZW, Chen JJ, Shi XY, Chen GL, Wu GT, Zhou DY, Zhou GQ, Huang JY, Lian L, et al. Genome variation in Colorectal cancer patient with liver Metastasis measured by whole-exome sequencing. J Gastrointest Oncol. 2021;12(2):507–15. doi: 10.21037/jgo-21-9. PubMed DOI PMC

Li C, Xu J, Wang X, Zhang C, Yu Z, Liu J, Tai Z, Luo Z, Yi X, Zhong Z. Whole exome and transcriptome sequencing reveal clonal evolution and exhibit immune-related features in metastatic colorectal tumors. Cell Death Discovery. 2021;7(1):222. doi: 10.1038/s41420-021-00607-9. PubMed DOI PMC

Feng L, Hong S, Gao J, Li J. Whole-exome sequencing characterized the Landscape of somatic mutations and pathways in Colorectal Cancer Liver Metastasis. J Oncol. 2019;2019:2684075. doi: 10.1155/2019/2684075. PubMed DOI PMC

Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S. Management of Colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol. 2014;11(8):446–59. doi: 10.1038/nrclinonc.2014.90. PubMed DOI

Hlavac V, Cervenkova L, Susova S, Holy P, Liska V, Vycital O, Sorejs O, Fiala O, Daum O, Soucek P. Exome sequencing of paired colorectal carcinomas and Synchronous Liver metastases for Prognosis and Therapy Prediction. JCO Precision Oncology. 2023;7:e2200557. doi: 10.1200/PO.22.00557. PubMed DOI

Li H. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics. 2014;30(20):2843–51. doi: 10.1093/bioinformatics/btu356. PubMed DOI PMC

Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43:111011–33. doi: 10.1002/0471250953.bi1110s43. PubMed DOI PMC

Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–5. doi: 10.1038/ng.2892. PubMed DOI PMC

Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–7. doi: 10.1093/nar/gkx1153. PubMed DOI PMC

Wang S, Li H, Song M, Tao Z, Wu T, He Z, Zhao X, Wu K, Liu XS. Copy number signature analysis tool and its application in Prostate cancer reveals distinct mutational processes and clinical outcomes. PLoS Genet. 2021;17(5):e1009557. doi: 10.1371/journal.pgen.1009557. PubMed DOI PMC

Albayrak A, Garrido-Castro AC, Giannakis M, Umeton R, Manam MD, Stover EH, Porter RL, Johnson BE, Liaw KL, Amonkar M, et al. Clinical Pan-cancer Assessment of Mismatch Repair Deficiency using Tumor-Only, targeted next-generation sequencing. JCO Precision Oncology. 2020;4:1084–97. doi: 10.1200/PO.20.00185. PubMed DOI PMC

Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide Copy Number Detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873. doi: 10.1371/journal.pcbi.1004873. PubMed DOI PMC

Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, Johnson J, Dougherty B, Barrett JC, Dry JR. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11):e108. doi: 10.1093/nar/gkw227. PubMed DOI PMC

Han X, Zhang S, Zhou DC, Wang D, He X, Yuan D, Li R, He J, Duan X, Wendl MC et al. MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data. Brief Bioinform 2021, 22(5). PubMed PMC

Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56. doi: 10.1101/gr.239244.118. PubMed DOI PMC

Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA, et al. Clinical sequencing defines the genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell. 2018;33(1):125. doi: 10.1016/j.ccell.2017.12.004. PubMed DOI PMC

Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, et al. Survival improvement for patients with metastatic Colorectal cancer over twenty years. NPJ Precision Oncology. 2023;7(1):16. doi: 10.1038/s41698-023-00353-4. PubMed DOI PMC

Shyr C, Tarailo-Graovac M, Gottlieb M, Lee JJ, van Karnebeek C. Wasserman WW: FLAGS, frequently mutated genes in public exomes. BMC Med Genomics. 2014;7:64. doi: 10.1186/s12920-014-0064-y. PubMed DOI PMC

Hellingman T, de Swart ME, Heymans MW, Jansma EP, van der Vliet HJ, Kazemier G. Repeat hepatectomy justified in patients with early recurrence of Colorectal cancer liver metastases: a systematic review and meta-analysis. Cancer Epidemiol. 2021;74:101977. doi: 10.1016/j.canep.2021.101977. PubMed DOI

Wong GYM, Mol B, Bhimani N, de Reuver P, Diakos C, Molloy MP, Hugh TJ. Recurrence patterns predict survival after resection of colorectal liver metastases. ANZ J Surg. 2022;92(9):2149–56. doi: 10.1111/ans.17835. PubMed DOI PMC

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, et al. Oncogenic signaling pathways in the Cancer Genome Atlas. Cell. 2018;173(2):321–337e310. doi: 10.1016/j.cell.2018.03.035. PubMed DOI PMC

Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(4):777–83. doi: 10.1158/1078-0432.CCR-17-1327. PubMed DOI PMC

Shirts BH, Konnick EQ, Upham S, Walsh T, Ranola JMO, Jacobson AL, King MC, Pearlman R, Hampel H, Pritchard CC. Using somatic mutations from tumors to classify variants in Mismatch Repair genes. Am J Hum Genet. 2018;103(1):19–29. doi: 10.1016/j.ajhg.2018.05.001. PubMed DOI PMC

Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of Metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765. doi: 10.1038/srep29765. PubMed DOI PMC

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high Colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. doi: 10.1016/S1470-2045(17)30422-9. PubMed DOI PMC

Kim TW, Taieb J, Gurary EB, Lerman N, Cui K, Yoshino T. Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced Colorectal cancer: Phase III LYNK-003. Future Oncol. 2021;17(36):5013–22. doi: 10.2217/fon-2021-0899. PubMed DOI

Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, et al. KRAS(G12C) inhibition with Sotorasib in Advanced Solid tumors. N Engl J Med. 2020;383(13):1207–17. doi: 10.1056/NEJMoa1917239. PubMed DOI PMC

Zhou X, Ji Y, Zhou J. Multiple strategies to develop small molecular KRAS directly bound inhibitors. Molecules 2023, 28(8). PubMed PMC

Zhang S, Carlsen L, Hernandez Borrero L, Seyhan AA, Tian X, El-Deiry WS. Advanced strategies for therapeutic targeting of wild-type and mutant p53 in Cancer. Biomolecules 2022, 12(4). PubMed PMC

Romanovsky E, Kluck K, Ourailidis I, Menzel M, Beck S, Ball M, Kazdal D, Christopoulos P, Schirmacher P, Stiewe T et al. Homogenous TP53mut-associated Tumor biology across mutation and cancer types revealed by transcriptome analysis. Cell Death Discovery 2023, 9(1). PubMed PMC

Zhang Y, Doran C, Le TK, Dreyfus B, Kola N, Sylvester BE, Lal L, Penrod JR, Meadows Shropshire S. Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell Lung cancer. Future Oncol. 2022;18(40):4509–23. doi: 10.2217/fon-2022-1117. PubMed DOI

Hlavac V, Holy P, Vaclavikova R, Rob L, Hruda M, Mrhalova M, Cernaj P, Bouda J, Soucek P. Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy. Life Sci Alliance 2022, 5(12). PubMed PMC

Huang YH, Lin PC, Su WC, Chan RH, Chen PC, Lin BW, Shen MR, Chen SH, Yeh YM. Association between altered Oncogenic Signaling Pathways and overall survival of patients with metastatic Colorectal Cancer. Diagnostics 2021, 11(12). PubMed PMC

Citarella A, Catanzaro G, Besharat ZM, Trocchianesi S, Barbagallo F, Gosti G, Leonetti M, Di Fiore A, Coppola L, Autilio TM et al. Hedgehog-GLI and Notch Pathways Sustain Chemoresistance and Invasiveness in Colorectal Cancer and Their Inhibition Restores Chemotherapy Efficacy. Cancers 2023, 15(5). PubMed PMC

Pencik J, Pham HTT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L. JAK-STAT signaling in cancer: from cytokines to non-coding genome. Cytokine. 2016;87:26–36. doi: 10.1016/j.cyto.2016.06.017. PubMed DOI PMC

Ugai T, Akimoto N, Haruki K, Harrison TA, Cao Y, Qu C, Chan AT, Campbell PT, Berndt SI, Buchanan DD et al. Prognostic role of detailed colorectal location and Tumor molecular features: analyses of 13,101 Colorectal cancer patients including 2994 early-onset cases. J Gastroenterol 2023. PubMed PMC

Yin BWT, Lloyd KO. Molecular cloning of the CA125 Ovarian cancer antigen - identification as a new mucin, MUC16. J Biol Chem. 2001;276(29):27371–5. doi: 10.1074/jbc.M103554200. PubMed DOI

Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60(11):3105–12. PubMed

Vega-Benedetti AF, Loi E, Moi L, Orrù S, Ziranu P, Pretta A, Lai EO, Puzzoni M, Ciccone L, Casadei-Gardini A et al. Colorectal Cancer early detection in Stool samples tracing CpG islands methylation alterations affecting gene expression. Int J Mol Sci 2020, 21(12). PubMed PMC

Sakamoto K, Kittikulsuth W, Miyako E, Steeve A, Ishimura R, Nakagawa S, Ago Y, Nishiyama A. The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody. PloS one 2023, 18(7). PubMed PMC

AACR Project GENIE Consortium: AACR Project GENIE Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7(8):818–31. doi: 10.1158/2159-8290.CD-17-0151. PubMed DOI PMC

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2020;31(11):1491–505. doi: 10.1016/j.annonc.2020.07.014. PubMed DOI

Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance